FibroBiologics, a clinical-stage biotech company, is advancing its fibroblast-based treatment platform to target Hantavirus pulmonary syndrome (HPS), a severe respiratory disease with high mortality and no approved therapies. Building on preclinical success in treating ARDS, a condition similar to HPS in lung damage and inflammation, the company aims to modulate the immune response and promote lung repair. FibroBiologics is conducting disease model evaluations and plans to engage regulators for clinical development, offering potential new hope for a currently untreatable global health threat.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
DMG Blockchain Solutions announced two strategic investments: one in MeetAmi Innovations, a Canadian fintech offering digital asset wealth management platforms, and another in Atomic47 Labs, an AI company focused on secure, sovereign AI infrastructur...
Gnosis (GNO) surged 13% in 24 hours, closing in on overtaking BONK by market capitalization to reach the 100th largest token spot. GNO's market cap stands at $303.88 million versus BONK's $330.07 million, requiring a price rise to about $125.48 for t...
